Press Releases July 7, 2026 07:00 AM

Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum

Avalo Therapeutics to engage investors at Leerink Partners Therapeutics Forum highlighting clinical progress in IL-1β targeting therapies

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
AVTX

Avalo Therapeutics announced its participation in the Leerink Partners Therapeutics Forum with management hosting investor meetings to discuss its clinical stage developments targeting the IL-1β pathway for immune-mediated inflammatory diseases. Their lead asset, abdakibart, showed positive Phase 2 topline data in hidradenitis suppurativa. The company is also advancing AVTX-010, a next-generation monoclonal antibody designed for extended dosing.

Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
AVTX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Avalo Therapeutics focuses on immune-mediated inflammatory diseases targeting the IL-1β pathway.
  • Positive Phase 2 clinical trial data reported for lead asset abdakibart in hidradenitis suppurativa.
  • Development of next-generation monoclonal antibody AVTX-010 to improve dosing intervals is underway.

WAYNE, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will host one-on-one investor meetings during the Leerink Partners Therapeutics Forum on July 15, 2026, in Boston.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Our lead asset, abdakibart, is an anti-IL-1β monoclonal antibody (mAb). Positive topline data was recently reported for abdakibart in a Phase 2 clinical trial in hidradenitis suppurativa (HS). In addition to HS, we’re exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. We are also advancing AVTX-010, a long-acting next-generation anti-IL-1β mAb designed to extend dosing intervals and build upon the differentiated profile established by abdakibart. For more information about Avalo, please visit www.avalotx.com.

For media and investor inquiries

Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
[email protected]
410-803-6793

or

Meru Advisors
Lauren Glaser
[email protected]


Risks

  • Clinical development risks as therapies are still in clinical stages and success in trials is uncertain.
  • Regulatory approval challenges for new biotechnology therapeutics.
  • Market adoption risks in competitive immune-mediated inflammatory disease treatments.

More from Press Releases

Harmony Biosciences to Participate in Upcoming Investor Conferences Nov 19, 2026 Pure Cycle Announces Record Financial Results For the Year Ended August 31, 2026 Nov 18, 2026 Sachem Capital Reports Third Quarter 2026 Results Nov 16, 2026 Inter&Co Delivers Record 3Q26 Net Income of US$76.1 Million, With Strong Growth, Higher Margin and Better Efficiency Nov 12, 2026 Super League to Report Third Quarter 2026 Financial Results on Monday, November 16, 2026 Nov 12, 2026